Trial Profile
A 52-Week,Multi-Center,Randomized,Double-Blind,Placebo-Controlled,Parallel Group Study in Patients With Mild Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Aug 2012
Price :
$35
*
At a glance
- Drugs Amilomotide (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 18 Jul 2012 NCT01023685 reports status of extension trial as completed.
- 18 Jul 2012 NCT01023685 reports status of extension trial as completed.
- 16 Nov 2011 Planned trial end date (Feb 2012) added as reported by ClinicalTrials.gov record (NCT01023685).